Tom Degenhardt
Overview
Explore the profile of Tom Degenhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollaender H, Ortner P, Koenig A, Erickson N, Hermelink K, Degenhardt T, et al.
Oncol Res Treat
. 2024 Aug;
47(10):509-517.
PMID: 39111294
Introduction: The interdisciplinary empowerment seminar aims to familiarize patients and informal caregivers (ICs) with supportive measures, focusing on understanding disease, therapy, and side effect management. Methods: The seminar, conducted in...
2.
Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaefgen B, et al.
Ann Surg Oncol
. 2023 Nov;
31(2):957-965.
PMID: 37947974
Background: Breast cancer patients with residual disease after neoadjuvant systemic treatment (NAST) have a worse prognosis compared with those achieving a pathologic complete response (pCR). Earlier identification of these patients...
3.
Harbeck N, Kates R, Schinkothe T, Schumacher J, Wuerstlein R, Degenhardt T, et al.
Cancer Treat Rev
. 2023 Oct;
121:102631.
PMID: 37862832
Background: Oral cancer medications offer advantages but also pose challenges for therapy management and adherence. An eHealth-based platform such as CANKADO can help to support therapy management by probing the...
4.
Degenhardt T, Fasching P, Luftner D, Muller V, Thomssen C, Schem C, et al.
Trials
. 2023 May;
24(1):338.
PMID: 37198674
Background: Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2...
5.
Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy
Dimpfl M, Mayr D, Schmoeckel E, Degenhardt T, Eggersmann T, Harbeck N, et al.
Breast Care (Basel)
. 2023 Jan;
17(5):501-507.
PMID: 36684405
Introduction: This project aimed to identify the frequency of a switch of hormone receptor (HR) and/or HER2 status after neoadjuvant chemotherapy (NAC) for early breast cancer. Methods: Tumor samples from...
6.
Pfob A, Sidey-Gibbons C, Rauch G, Thomas B, Schaefgen B, Kuemmel S, et al.
J Clin Oncol
. 2022 Feb;
40(17):1903-1915.
PMID: 35108029
Purpose: Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in 40%-70% of women with breast cancer. These patients may not need surgery as all local tumor has already been...
7.
Monti M, Degenhardt T, Brain E, Wuerstlein R, Argusti A, Puntoni M, et al.
Front Med (Lausanne)
. 2022 Jan;
8:817678.
PMID: 35096909
Academic research is important to face unmet medical needs. The Oncological community encounters many hurdles in setting up multicenter investigator-driven trials mainly due to administrative complexity. The purpose of a...
8.
Forster M, Wuerstlein R, Koenig A, Amann N, Beyer S, Kaltofen T, et al.
Breast
. 2021 Nov;
60:214-222.
PMID: 34736092
Introduction: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about...
9.
Kolben T, Beyer S, Ghasemi S, Hermelink K, Meister S, Degenhardt T, et al.
Breast Care (Basel)
. 2021 Oct;
16(4):343-349.
PMID: 34602939
Introduction: Breast cancer (BC) is the most common cancer in women worldwide. Despite screening and information efforts, about 10% of patients present with tumor size T3 or T4 at primary...
10.
Ni H, Kumbrink J, Mayr D, Seiler A, Hagemann F, Degenhardt T, et al.
J Pers Med
. 2021 Sep;
11(9).
PMID: 34575612
Molecular factors that drive metastasis in premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (EBC) are largely unknown. To identify...